INTRODUCTION: Cerebral vasospasm is a severe complication of subarachnoid hemorrhage (SAH). The calcium channel inhibitor nimodipine has been used for treatment of cerebral vasospasm. No evidence-based recommendations for local nimodipine administration at the site of vasospasm exist. The purpose of this study was to quantify nimodipine's local vasodilatory effect in an ex vivo model of SAH-induced vasospasm. METHODS: SAH-induced vasospasm was modeled by contracting isolated segments of rat superior cerebellar arteries with a combination of serotonin and a synthetic analog of prostaglandin A(2). A pressure myograph system was used to determine vessel reactivity of spastic as well as non-spastic arteries. RESULTS: Compared to the initial vessel diameter, a combination of serotonin and prostaglandin induced considerable vasospasm (55 ± 2.5 % contraction; n = 12; p < 0.001). Locally applied nimodipine dilated the arteries in a concentration-dependent manner starting at concentrations as low as 1 nM (n = 12; p < 0.05). Concentrations higher than 100 nM did not relevantly increase the vasodilatory effect. Nimodipine's vasodilatory effect was smaller in spastic than in non-spastic vessels (n = 12; p < 0.05), which we assume to be due to structural changes in the vessel wall. CONCLUSION: The described ex vivo model allows to investigate the dose-dependent efficacy of spasmolytic drugs prior to in vivo experiments. Low concentrations of locally applied nimodipine have a strong vasodilatory effect, which is of relevance when considering the local application of nimodipine in cerebral vasospasm.
INTRODUCTION:Cerebral vasospasm is a severe complication of subarachnoid hemorrhage (SAH). The calcium channel inhibitor nimodipine has been used for treatment of cerebral vasospasm. No evidence-based recommendations for local nimodipine administration at the site of vasospasm exist. The purpose of this study was to quantify nimodipine's local vasodilatory effect in an ex vivo model of SAH-induced vasospasm. METHODS:SAH-induced vasospasm was modeled by contracting isolated segments of rat superior cerebellar arteries with a combination of serotonin and a synthetic analog of prostaglandin A(2). A pressure myograph system was used to determine vessel reactivity of spastic as well as non-spastic arteries. RESULTS: Compared to the initial vessel diameter, a combination of serotonin and prostaglandin induced considerable vasospasm (55 ± 2.5 % contraction; n = 12; p < 0.001). Locally applied nimodipine dilated the arteries in a concentration-dependent manner starting at concentrations as low as 1 nM (n = 12; p < 0.05). Concentrations higher than 100 nM did not relevantly increase the vasodilatory effect. Nimodipine's vasodilatory effect was smaller in spastic than in non-spastic vessels (n = 12; p < 0.05), which we assume to be due to structural changes in the vessel wall. CONCLUSION: The described ex vivo model allows to investigate the dose-dependent efficacy of spasmolytic drugs prior to in vivo experiments. Low concentrations of locally applied nimodipine have a strong vasodilatory effect, which is of relevance when considering the local application of nimodipine in cerebral vasospasm.
Authors: Michael A Hill; Simon J Potocnik; Luis A Martinez-Lemus; Gerald A Meininger Journal: Am J Physiol Heart Circ Physiol Date: 2003-04-24 Impact factor: 4.733
Authors: M Murat Firat; Veli Gelebek; Hakan S Orer; Deniz Belen; Ahmet K Firat; Ferhun Balkanci Journal: AJNR Am J Neuroradiol Date: 2005 Jun-Jul Impact factor: 3.825
Authors: F Seker; J Hesser; M A Brockmann; E Neumaier-Probst; C Groden; R Schubert; C Brockmann Journal: Clin Neuroradiol Date: 2015-09-08 Impact factor: 3.649
Authors: Vanessa Weyer; Máté E Maros; Stefanie Kirschner; Samantha Krost-Reuhl; Christoph Groden; Martin Kramer; Marc A Brockmann; Andrea Kronfeld Journal: PLoS One Date: 2022-10-13 Impact factor: 3.752
Authors: Axel Neulen; Svenja Kunzelmann; Michael Kosterhon; Tobias Pantel; Maximilian Stein; Manfred Berres; Florian Ringel; Marc A Brockmann; Carolin Brockmann; Sven R Kantelhardt Journal: Front Neurol Date: 2020-01-30 Impact factor: 4.003